The visceral fat that wraps around organs is actually more metabolically active and responsive to the hormonal changes GLP-1 therapy creates
Reviewed May 2026
All of the dynamics around GLP-1s, compounding shortage workarounds, and potential for DTC telehealth fallout I described last August seem to be playing out in 2025
These medications include semaglutide (Ozempic, Wegovy), dulaglutide (Trulicity), liraglutide (Victoza, Saxenda), exenatide (Byetta, Bydureon BCise), and tirzepatide (Mounjaro, Zepbound)though tirzepatide is technically a dual GIP/GLP-1 receptor agonist
Pharmacy Operations: Workflow, Counseling, and Risk Management For pharmacies, the rise of GLP-1 therapies has not been a simple increase in prescription volume
Holly Lofton (NYU Langone Health) details the overwhelming demand for these drugs, even among those not strictly medically eligible